Dr. Reddy’s Laboratories Ltd has announced the launch of BixiBat®, a first-in-class drug for treating chronic constipation in India. This innovative medication, known scientifically as Elobixibat, has received approval from the Central Drugs Standard Control Organisation (CDSCO) following the successful completion of Dr. Reddy’s Phase-3 clinical trials.
As the first company to introduce Elobixibat in India, Dr. Reddy’s aims to provide a new solution for those suffering from chronic constipation. It works by inhibiting the reabsorption of bile acids from the ileum, raising their concentration in the colonic lumen and causing increased bowel movements owing to stimulation of both colonic motility and fluid secretion, regardless of transit speed.
M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s, stated, “The launch of this first-in-class drug is the latest in our continued efforts to bring novel molecules to patients in India. With over three decades of expertise and leadership in the gastrointestinal segment in India through trusted products such as Omez®, Razo™, Econorm®, and Redotil™, this latest offering will help us address unmet patient needs and further improve quality of life. The clinical studies for BixiBat® have demonstrated significantly better and promising outcomes, making it a breakthrough drug in the management of chronic constipation and enhancing the current standard of care for its treatment in India.”
